Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models

Lee, Laifong, Sudentas, Paul, Donohue, Brian, Asrican, Kirsten, Worku, Aelaf, Walker, Victoria, Sun, Yanping, Schmidt, Karl, Albert, Mitchell S., El‐Hashemite, Nisreen, Lader, Alan S., Onda, Hiroaki, Zhang, Hongbing, Kwiatkowski, David J., Dabora, Sandra L.·2005·Genes, Chromosomes and Cancer

Abstract

Tuberous sclerosis complex (TSC) is a familial tumor disorder for which there is no effective medical therapy. Disease‐causing mutations in the TSC1 or TSC2 gene lead to increased mammalian target of rapamycin (mTOR) kinase activity in the conserved mTOR signaling pathway, which regulates nutrient uptake, cell growth, and protein translation. The normal function of TSC1 and TSC2 gene products is to form a complex that reduces mTOR kinase activity. Thus, mTOR kinase inhibition may be a useful targeted therapeutic approach. Elevated interferon‐gamma (IFN‐γ) expression is associated with decreased severity of kidney tumors in TSC patients and mouse models; therefore, IFN‐γ also has therapeutic potential. We studied cohorts of Tsc2+/− mice and a novel mouse model of Tsc2‐null tumors in order to evaluate the efficacy of targeted therapy for TSC. We found that treatment with either an mTOR kinase inhibitor (CCI‐779, a rapamycin analog) or with IFN‐γ reduced the severity of TSC‐related disease without significant toxicity. These results constitute definitive preclinical data that justify proceeding with clinical trials using these agents in selected patients with TSC and related disorders. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gcc.20118

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 167

Metadata

Authors
Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M. S., El‐Hashemite, N., Lader, A. S., Onda, H., Zhang, H., Kwiatkowski, D. J., & Dabora, S. L.
Venue
Genes, Chromosomes and Cancer
Publisher
Wiley
Published
2004-12
Volume
42
Issue
3
Pages
213-227
ISSN
  • 1045-2257 (ISSN-L)
  • 1098-2264
OpenAlex
W2042530540
Cited by
167
References
5
FWCI
5.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models. https://app.cochat.ai/papers/10.1002/gcc.20118
The paper
Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M. S., El‐Hashemite, N., Lader, A. S., Onda, H., Zhang, H., Kwiatkowski, D. J., & Dabora, S. L. (2005). Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.20118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.